{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:59:16Z","timestamp":1793026756554,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic central serous chorioretinopathy (cCSC) can lead to irreversible visual impairment. Traditional treatment methods are limited by their efficacy and the risk of complications. Subthreshold micropulse laser (SML) therapy has emerged as a promising treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study systematically evaluated the efficacy and safety of SML for treating cCSC, providing evidence-based clinical recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Cochrane Library, and Web of Science for studies published up to January 10, 2025, evaluating SML for cCSC. Eligible designs included randomized controlled trials (RCTs), prospective cohort studies, and case series. Two researchers independently performed literature screening, data extraction, and quality assessment using RoB 2, NOS, and JBI tools, respectively. The certainty of evidence was evaluated using the GRADE system. Meta-analysis was conducted using STATA 18.0 to pool the effects on visual acuity (BCVA) and retinal morphology (CMT, CT, CRT). Subgroup analyses were performed based on laser wavelengths (527, 532, 577, and 810 nm).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,412 articles were identified, and 21 studies were included, with a total sample size of 939 eyes. Meta-analysis demonstrated that SML significantly improved the best-corrected visual acuity (BCVA) of cCSC patients, with a pooled effect size of [SMD = \u22120.74, 95% CI (\u22121.14, \u22120.33),\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001]. The efficacy was consistent across different wavelengths (527, 532, 577, 810 nm). Regarding retinal morphological parameters, SML significantly reduced the central macular thickness [CMT, SMD = \u22122.15; 95% CI (\u22123.82, \u22120.47),\n                      <jats:italic>P<\/jats:italic>\n                      = 0.018], choroidal thickness [CT, SMD = \u22120.43; 95% CI (\u22120.79, \u22120.08),\n                      <jats:italic>P<\/jats:italic>\n                      = 0.025], and central retinal thickness [CRT, SMD = \u22121.12; 95% CI (\u22121.34, \u22120.90),\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001]. Although improvements in subretinal fluid height (SRFH) were not statistical significance, most studies indicated a positive trend. Additionally, SML demonstrated a high safety profile for treating cCSC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SML significantly improves visual function and retinal morphology in cCSC patients, demonstrating consistent efficacy across different wavelengths and providing a safe, effective treatment option for cCSC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1785787","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:12:07Z","timestamp":1773418327000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of subthreshold micropulse laser for chronic central serous chorioretinopathy: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Ocular Fundus Diseases, Nanjing Aier Eye Hospital, Nanjing City","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ocular Fundus Diseases, Nanjing Aier Eye Hospital, Nanjing City","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.31348\/2023\/27","article-title":"Central serous chorioretinopathy. A Review.","volume":"80","author":"Mysl\u00edk Manethov\u00e1","year":"2024","journal-title":"Cesk Slov Oftalmol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis.","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: towards an evidence-based treatment guideline.","volume":"73","author":"van Rijssen","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.2147\/OPTH.S220845","article-title":"Central Serous Chorioretinopathy: pathogenesis and management.","volume":"13","author":"Semeraro","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101236","DOI":"10.1016\/j.preteyeres.2024.101236","article-title":"Central serous chorioretinopathy: an evidence-based treatment guideline.","volume":"101","author":"Feenstra","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4103\/2211-5056.362040","article-title":"Central serous chorioretinopathy: treatment.","volume":"12","author":"Park","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41433-019-0381-7","article-title":"Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.","volume":"33","author":"Sartini","year":"2019","journal-title":"Eye"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s12325-017-0559-y","article-title":"A review of subthreshold micropulse laser for treatment of macular disorders.","volume":"34","author":"Scholz","year":"2017","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/08820538.2015.1114837","article-title":"Subthreshold diode micropulse laser: a review.","volume":"31","author":"Brader","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/medicina59081388","article-title":"Micropulse laser therapy as an integral part of eye disease management.","volume":"59","author":"Bodea","year":"2023","journal-title":"Medicina"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10792-024-02973-6","article-title":"Subthreshold micropulse diode laser treatment in diabetic macular edema: biological impact, therapeutic effects, and safety.","volume":"44","author":"Mei","year":"2024","journal-title":"Int Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE Trial.","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3190136","DOI":"10.1155\/2020\/3190136","article-title":"Long-term effects of half-time photodynamic therapy on retinal sensitivity in eyes with chronic central serous chorioretinopathy.","volume":"2020","author":"Iwase","year":"2020","journal-title":"Biomed Res Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3390\/jcm12031127","article-title":"Effectiveness, safety and choroidal changes of a fovea-sparing technique for the treatment of chronic central serous chorioretinopathy with yellow subthreshold laser.","volume":"12","author":"Torrellas","year":"2023","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41433-019-0692-8","article-title":"Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy.","volume":"34","author":"Sun","year":"2020","journal-title":"Eye"},{"key":"B16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s10103-020-03129-5","article-title":"The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy.","volume":"36","author":"Uzlu","year":"2021","journal-title":"Lasers Med Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.18240\/ijo.2020.09.11","article-title":"Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy.","volume":"13","author":"I\u015f\u0131k","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103221","DOI":"10.1016\/j.pdpdt.2022.103221","article-title":"Electrophysiological and anatomical outcomes of subthreshold micropulse laser therapy in chronic central serous chorioretinopathy.","volume":"41","author":"Kayhan","year":"2023","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10103-024-04030-1","article-title":"Evaluation of changes in macular structures after subthreshold micropulse laser therapy on chronic central serous chorioretinopathy.","volume":"39","author":"Liu","year":"2024","journal-title":"Lasers Med Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.pdpdt.2024.104295","article-title":"Functional and anatomical results of subthreshold micropulse laser as rescue treatment for central serous chorioretinopathy after verteporfin shortage.","volume":"49","author":"Oribio-Quinto","year":"2024","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00417-017-3783-x","article-title":"Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser.","volume":"255","author":"Gaw\u00eacki","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1177\/11206721211064021","article-title":"Navigated micropulse laser for central serous chorioretinopathy: efficacy, safety, and predictive factors of treatment response.","volume":"32","author":"Amoroso","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41433-018-0309-7","article-title":"Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years.","volume":"33","author":"Kim","year":"2019","journal-title":"Eye"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00417-015-2965-7","article-title":"Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy.","volume":"253","author":"Kim","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0184112","DOI":"10.1371\/journal.pone.0184112","article-title":"Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy.","volume":"12","author":"Maruko","year":"2017","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9750395","DOI":"10.1155\/2024\/9750395","article-title":"Subthreshold micropulse laser (577 nm) therapy with an individual approach for power titration in patients with chronic central serous chorioretinopathy (pilot study).","volume":"2024","author":"Kustryn","year":"2024","journal-title":"J Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.mjafi.2022.12.011","article-title":"532 nm versus 810 nm subthreshold micropulse laser in treatment of non-resolving central serous chorioretinopathy: a randomized controlled trial.","volume":"80","author":"Ambiya","year":"2024","journal-title":"Med J Armed Forces India"},{"key":"B28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3928\/23258160-20130909-08","article-title":"Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial.","volume":"44","author":"Roisman","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"B29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1177\/112067210801800613","article-title":"Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study.","volume":"18","author":"Lanzetta","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2515841420945107","DOI":"10.1177\/2515841420945107","article-title":"Role of 532 nm transfoveal subthreshold micropulse laser in non-resolving central serous chorioretinopathy with subfoveal leaks.","volume":"12","author":"Ambiya","year":"2020","journal-title":"Ther Adv Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3341\/kjo.2020.0112","article-title":"Evaluation of the safety and efficacy of selective retina therapy laser treatment in patients with central serous chorioretinopathy.","volume":"35","author":"Oh","year":"2021","journal-title":"Korean J Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40662-023-00349-y","article-title":"Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies.","volume":"10","author":"Zhang","year":"2023","journal-title":"Eye Vis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/IAE.0000000000000285","article-title":"Low-intensity\/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy.","volume":"35","author":"Malik","year":"2015","journal-title":"Retina"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40123-023-00698-w","article-title":"Yellow subthreshold micropulse laser in retinal diseases: an in-depth analysis and review of the literature.","volume":"12","author":"Iovino","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000439600","article-title":"Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy.","volume":"234","author":"Scholz","year":"2015","journal-title":"Ophthalmologica"},{"key":"B36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/eye.2014.315","article-title":"Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome.","volume":"29","author":"Yadav","year":"2015","journal-title":"Eye."},{"key":"B37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/eye.2017.293","article-title":"Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.","volume":"32","author":"Arsan","year":"2018","journal-title":"Eye"},{"key":"B38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/02713683.2021.1962360","article-title":"Determination of micropulse modes with targeted damage to the retinal pigment epithelium using computer modeling for the development of selective individual micropulse retinal therapy.","volume":"47","author":"Ivanova","year":"2022","journal-title":"Curr Eye Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1494402","DOI":"10.3389\/fmed.2024.1494402","article-title":"The safe lowest effective power of subthreshold micropulse laser treatment in Chinese patients with acute or chronic central serous chorioretinopathy.","volume":"11","author":"Xie","year":"2024","journal-title":"Front Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1785787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:12:08Z","timestamp":1773418328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1785787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":39,"alternative-id":["10.3389\/fmed.2026.1785787"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1785787","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1785787"}}